Physician profile
Aleda A Longwell
NPI 1093960643
$4,263.45
in general payments reported to CMS, 2019-2025
22 companies · $1,831 in 2025
The $1,831 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $600 · 2024: $1,832 · 2025: $1,831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,088 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,088.47 |
| Education | $174.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $696.24 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $490.69 | 2023-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $445.40 | 2023-2025 | Winlevi, Absorica Ld |
| Genzyme Corporation | $421.65 | 2023-2025 | |
| Galderma Laboratories, L.P. | $332.45 | 2023-2025 | Nemluvio |
| Incyte Corporation | $315.01 | 2023-2025 | Opzelura |
| Janssen Biotech, INC. | $285.91 | 2024-2025 | Tremfya, Simponi, Stelara |
| E.R. Squibb & Sons, L.L.C. | $183.94 | 2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $170.37 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $163.34 | 2024 | Adbry |
| Novartis Pharmaceuticals Corporation | $139.64 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $94.99 | 2025 | |
| Dermavant Sciences, INC. | $89.16 | 2023-2024 | Vtama |
| Pfizer INC. | $86.32 | 2023-2025 | |
| Lilly USA, LLC | $69.57 | 2023-2024 | Taltz, Olumiant |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $64.50 | 2023-2024 | Otezla |
| Organon LLC | $63.76 | 2025 | Nexplanon, Vtama |
| Merz North America, INC. | $54.97 | 2024-2025 | |
| Almirall LLC | $29.91 | 2025 | Klisyri |
| Cipher Pharmaceuticals US LLC | $24.26 | 2025 | Spinosad, Natroba |
| Strata Skin Sciences, INC. | $20.84 | 2025 | Xtrac |
| Ucb, INC. | $20.53 | 2025 | Bimzelx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aleda Longwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.